Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors.
CDK 4/6 inhibitors
adherence
advanced breast cancer
beliefs about medicines
depressive symptoms
oral anticancer therapy
Journal
Acta pharmaceutica (Zagreb, Croatia)
ISSN: 1846-9558
Titre abrégé: Acta Pharm
Pays: Poland
ID NLM: 9303678
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
accepted:
30
11
2023
medline:
26
12
2023
pubmed:
26
12
2023
entrez:
26
12
2023
Statut:
epublish
Résumé
Treatment adherence is crucial for optimal outcomes in advanced breast cancer, but can be challenging due to various factors,
Identifiants
pubmed: 38147481
pii: acph-2023-0045
doi: 10.2478/acph-2023-0045
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
633-654Informations de copyright
© 2023 Matea Baković et al., published by Sciendo.
Références
C. Lin, R. Clark, P. Tu, H. B. Bosworth and L. L. Zullig, Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers, Breast Cancer Res. Treat . 165 (2) (2017) 247–260; https://doi.org/10.1007/s10549-017-4317-2
V. J. O’neill and C. J. Twelves, Oral cancer treatment: developments in chemotherapy and beyond, Br. J. Cancer 87 (9) (2002) 933–937; https://doi.org/10.1038/sj.bjc.6600591
V. Gebbia, G. Bellavia, F. Ferra and M. R. Valerio, Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents, Expert Opin. Drug Saf. 11 (1) (2012) 49–59; https://doi.org/10.1517/14740338.2011.645803
B. A. Given, S. L. Spoelstra and M. Grant, The challenges of oral agents as antineoplastic treatments, Semin. Oncol. Nurs. 27 (2) (2011) 93–103; https://doi.org/10.1016/j.soncn.2011.02.003
R. Lasala and F. Santoleri, Association between adherence to oral therapies in cancer patients and clinical outcome: a systematic review of the literature, Br. J. Clin. Pharmacol . 88 (5) (2022) 1999–2018; https://doi.org/10.1111/bcp.15147
L. A. Decosterd, N. Widmer, K. Zaman, E. Cardoso, T. Buclin and C. Csajka, Therapeutic drug monitoring of targeted anticancer therapy, Biomark Med . 9 (9) (2015) 887–893; https://doi.org/10.2217/bmm.15.78
T. M. Atkinson, V. M. Rodríguez, M. Gordon, I. K. Avildsen, J. C. Emanu, S. T. Jewell, K. A. Anselmi and P. K. Ginex, The association between patient-reported and objective oral anticancer medication adherence measures: a systematic review, Oncol. Nurs. Forum . 43 (5) (2016) 576–582; https://doi.org/10.1188/16.ONF.576-582
K. Ruddy, E. Mayer and A. Partridge, Patient adherence and persistence with oral anticancer treatment, CA Cancer J. Clin. 59 (1) (2009) 56–66; https://doi.org/10.3322/caac.20004
A. Vyas, A. Descoteaux, S. Kogut, M. A. Parikh, P. J. Campbell, A. Green and K. Westrich, Predictors of adherence to oral anticancer medications: an analysis of 2010-2018 US nationwide claims, J. Manag. Care Spec. Pharm. 28 (8) (2022) 831–844; https://doi.org/10.18553/jmcp.2022.28.8.831
A. M. Levine, J. L. Richardson, G. Marks, K. Chan, J. Graham, J. N. Selser, C. Kishbaugh, D. R. Shelton and C. A. Johnson, Compliance with oral drug therapy in patients with hematologic malignancy, J. Clin. Oncol. 5 (9) (1987) 1469–1476; https://doi.org/10.1200/JCO.1987.5.9.1469
C. R. Lee, P. W. Nicholson, R. L. Souhami and A. A. Deshmukh, Patient compliance with oral chemo-therapy as assessed by a novel electronic technique, J. Clin. Oncol. 10 (6) (1992) 1007–1013; https://doi.org/10.1200/JCO.1992.10.6.1007
L. Atkins and L. Fallowfield, Intentional and non-intentional non-adherence to medication amongst breast cancer patients, Eur. J. Cancer 42 (14) (2006) 2271–2276; https://doi.org/10.1016/j.ejca.2006.03.004
J. Ferlay, M. Colombet, I. Soerjomataram, C. Mathers, D. M. Parkin, M. Piñeros, A. Znaor and F. Bray, Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods, Int. J. Cancer . 144 (8) (2019) 1941–1953; https://doi.org/10.1002/ijc.31937
M. C. Kirk and C. A. Hudis, Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer, Clin. Breast Cancer 8 (2) (2008) 155–161; https://doi.org/10.3816/CBC.2008.n.016
A. H. Partridge, P. S. Wang, E. P. Winer and J. Avorn, Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer, J. Clin. Oncol. 21 (4) (2003) 602–606; https://doi.org/10.1200/JCO.2003.07.071
T. L. Lash, M. P. Fox, J. L. Westrup, A. K. Fink and R. A. Silliman, Adherence to tamoxifen over the five-year course, Breast Cancer Res. Treat. 99 (2) (2006) 215–220; https://doi.org/10.1007/s10549-006-9193-0
A. K. Fink, J. Gurwitz, W. Rakowski, E. Guadagnoli and R. A. Silliman, Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer, J. Clin. Oncol. 22 (16) (2004) 3309–3315; https://doi.org/10.1200/JCO.2004.11.064
T. I. Barron, R. M. Connolly, K. Bennett, J. Feely and M. J. Kennedy, Early discontinuation of tamoxifen: a lesson for oncologists, Cancer 109 (5) (2007) 832–839; https://doi.org/10.1002/cncr.22485
M. Giuliano, F. Schettini, C. Rognoni, M. Milani, G. Jerusalem, T. Bachelot, M. De Laurentiis, G. Thomas, P. De Placido, G. Arpino, S. De Placido, M. Cristofanilli, A. Giordano, F. Puglisi, B. Pistilli, A. Prat, L. Del Mastro, S. Venturini and D. Generali, Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis, Lancet Oncol. 20 (10) (2019) 1360–1369; https://doi.org/10.1016/S1470-2045(19)30420-6
R. Addeo, P. Iodice, L. Maiorino, A. Febbraro, P. Incoronato, A. Pisano, M. Bianco, R. Mabilia, F. Riccardi and S. Del Prete, Acceptance and adherence of oral endocrine therapy in women with metastatic breast cancer: exacampania group study, Breast J. 21 (3) (2015) 326–328; https://doi.org/10.1111/tbj.12409
C. McCowan, J. Shearer, P. T. Donnan, J. A. Dewar, M. Crilly, A. M. Thompson and T. P. Fahey, Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer, Br. J. Cancer 99 (11) (2008) 1763–1768; https://doi.org/10.1038/sj.bjc.6604758
C. Owusu, D. S. M. Buist, T. S. Field, T. L. Lash, S. S. Thwin, A. M. Geiger, V. P. Quinn, F. Frost, M. Prout, M. U. Yood, F. Wei and R. A. Silliman, Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer, J. Clin. Oncol. 26 (4) (2008) 549–555; https://doi.org/10.1200/JCO.2006.10.1022
R. L. Sedjo and S. Devine, Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer, Breast Cancer Res. Treat. 125 (1) (2011) 191–200; https://doi.org/10.1007/s10549-010-0952-6
R. Simon, J. Latreille, C. Matte, P. Desjardins and E. Bergeron, Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up, Can. J. Surg. 57 (1) (2014) 26–32; https://doi.org/10.1503/cjs.006211
V. Wong, R. de Boer, S. Baron-Hay, R. Blum, F. Boyle, S. Chua, K. Clarke, K. Cuff, M. Green, E. Lim, K. Mok, L. Nott, M. Nottage, A. Tafreshi, D. Tsoi, A. Uccellini, W. Hong, P. Gibbs and S.W. Lok, Real-world outcomes of ribociclib and aromatase inhibitor use in first line hormone receptor positive, HER2-negative metastatic breast cancer, Clin. Breast Cancer 22 (8) (2022) 792–800; https://doi.org/10.1016/j.clbc.2022.08.011
M. Piezzo, P. Chiodini, M. Riemma, S. Cocco, R. Caputo, D. Cianniello, G. Di Gioia, V. Di Lauro, F. Di Rella, G. Fusco, G. Iodice, F. Nuzzo, C. Pacilio, M. Pensabene and M. De Laurentiis, Progression-free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis, Int. J. Mol. Sci . 21 (17) (2020) Article ID 6400 (17 pages); https://doi.org/10.3390/ijms21176400
C. Bandiera, I. Locatelli, P. Courlet, E. Cardoso, K. Zaman, A. Stravodimou, A. Dolcan, A. Sarivalasis, J. P. Zurcher, V. Aedo-Lopez, J. Dotta-Celio, S. Peters, M. Guidi, A. D. Wagner, C. Csajka and M. P. Schneider, Adherence to the CDK 4/6 inhibitor palbociclib and omission of dose management supported by pharmacometric modelling as part of the OpTAT study, Cancers (Basel) 15 (1) (2023) Article ID 316 (19 pages); https://doi.org/10.3390/cancers15010316
C. C. Conley, M. K. McIntyre, N. A. Pensak, F. Lynce, D. Graham, R. Ismail-Khan, K. Lopez, S. T. Vadaparampil and S. C. O’Neill, Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study, Breast Cancer Res. Treat. 192 (2) (2022) 385–399; https://doi.org/10.1007/s10549-022-06518-2
L. Turković, L. Bočkor, O. Ekpenyong, T. Silovski, M. Lovrić, S. Crnković, B. Nigović and M. Sertić, Development and validation of a novel LC-MS/MS method for the simultaneous determination of abemaciclib, palbociclib, ribociclib, anastrozole, letrozole, and fulvestrant in plasma samples: a pre-requisite for personalized breast cancer treatment, Pharmaceuticals 15 (5) (2022) Article ID 614 (19 pages); https://doi.org/10.3390/ph15050614
A. H. Y. Chan, R. Horne, M. Hankins and C. Chisari, The medication adherence report scale: a measurement tool for eliciting patients’ reports of nonadherence, Br. J. Clin. Pharmacol. 86 (7) (2020) 1281–1288; https://doi.org/10.1111/bcp.14193
R. Horne, K. Faasse, V. Cooper, M. A. Diefenbach, H. Leventhal, E. Leventhal and K. J. Petrie, The perceived sensitivity to medicines (PSM) scale: an evaluation of validity and reliability, Br. J. Health Psychol. 18 (1) (2013) 18–30; https://doi.org/10.1111/j.2044-8287.2012.02071.x
R. Horne, J. Weinman and M. Hankins, The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication, Psychol. Health 14 (1) (1999) 1–24; https://doi.org/10.1080/08870449908407311
R. Horne and J. Weinman, Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness, J. Psychosom. Res. 47 (6) (1999) 555–567; https://doi.org/10.1016/S0022-3999(99)00057-4
D. Wild, A. Grove, M. Martin, S. Eremenco, S. McElroy, A. Verjee-Lorenz and P. Erikson, Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation, Value Health 8 (2) (2005) 94–104; https://doi.org/10.1111/j.1524-4733.2005.04054.x
A. T. Beck, R. Steer, J. Brown, Manual for the Beck Depression Inventory-II ; Psychological Corporation, San Antonio 1996.
C. Louwrens Braal, E. M. Jongbloed, S. M. Wilting, R. H. J. Mathijssen, S. L. W. Koolen and A. Jager, Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences, Drugs 81 (3) (2021) 317–331; https://doi.org/10.1007/s40265-020-01461-2
K. Tamura, H. Mukai, Y. Naito, K. Yonemori, M. Kodaira, Y. Tanabe, N. Yamamoto, S. Osera, M. Sasaki, Y. Mori, S. Hashigaki, T. Nagasawa, Y. Umeyama and T. Yoshino, Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients, Cancer Sci. 107 (6) (2016) 755–763; https://doi.org/10.1111/cas.12932
T. S. Samant, S. Dhuria, Y. Lu, M. Laisney, S. Yang, A. Grandeury, M. Mueller-Zsigmondy, K. Umehara, F. Huth, M. Miller, C. Germa and M. Elmeliegy, Ribociclib bioavailability is not affected by gastric pH changes or food intake: in silico and clinical evaluations, Clin. Pharmacol. Ther. 104 (2) (2018) 374–383; https://doi.org/10.1002/cpt.940
A. Le Marouille, E. Petit, C. Kaderbhaï, I. Desmoulins, A. Hennequin, D. Mayeur, J. D. Fumet, S. Ladoire, Z. Tharin, S. Ayati, S. Ilie, B. Royer and A. Schmitt, Pharmacokinetic/pharmacodynamic model of neutropenia in real-life palbociclib-treated patients, Pharmaceutics 13 (10) (2021) Article ID 1708 (14 pages); https://doi.org/10.3390/pharmaceutics13101708
P. Courlet, E. Cardoso, C. Bandiera, A. Stravodimou, J. P. Zurcher, H. Chtioui, I. Locatelli, L. A. Decosterd, L. Darnaud, B. Blanchet, J. Alexandre, A. D. Wagner, K. Zaman, M. P. Schneider, M. Guidi and C. Csajka, Population pharmacokinetics of palbociclib and its correlation with clinical efficacy and safety in patients with advanced breast cancer, Pharmaceutics 14 (7) (2022) Article ID 1317 (17 pages); https://doi.org/10.3390/pharmaceutics14071317
P. Kardas, P. Lewek and M. Matyjaszczyk, Determinants of patient adherence: a review of systematic reviews, Front. Pharmacol. 4 (2013) Article ID 91 (16 pages); https://doi.org/10.3389/fphar.2013.00091
G. Kimmick, S. N. Edmond, H. B. Bosworth, J. Peppercorn, P. K. Marcom, K. Blackwell, F. J. Keefe and R. A. Shelby, Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy, Breast 24 (5) (2015) 630–636; https://doi.org/10.1016/j.breast.2015.06.010
H. Wouters, A. M. Stiggelbout, M. L. Bouvy, G. A. Maatman, E. C. G. Van Geffen, R. Vree, J. W. Nortier and L. Van Dijk, Endocrine therapy for breast cancer: assessing an array of women’s treatment experiences and perceptions, their perceived self-efficacy and nonadherence, Clin. Breast Cancer 14 (6) (2014) 460–467; https://doi.org/10.1016/j.clbc.2014.04.005
C. Bolman, T. G. Arwert and T. Völlink, Adherence to prophylactic asthma medication: habit strength and cognitions, Heart Lung 40 (1) (2011) 63–75; https://doi.org/10.1016/j.hrtlng.2010.02.003
L. Alison Phillips, H. Leventhal and E. A. Leventhal, Assessing theoretical predictors of long-term medication adherence: patients’ treatment-related beliefs, experiential feedback and habit development, Psychol. Health 28 (10) (2013) 1135–1151; https://doi.org/10.1080/08870446.2013.793798
A. S. Gadkari and C. A. Mchorney, Unintentional non-adherence to chronic prescription medications: how unintentional is it really?, BMC Health Serv. Res. 12 (2012) Article ID 98 (12 pages); https://doi.org/10.1186/1472-6963-12-98
M. Meegdes, S. M. E. Geurts, F. L. G. Erdkamp, M. W. Dercksen, B. E. P. J. Vriens, K. N. A. Aaldering, M. J. A. E. Pepels, L. M. H. van de Winkel, N. J. A. Teeuwen, M. de Boer and V. C. G. Tjan-Heijnen, The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2-advanced breast cancer patients: a study of the Dutch SONABRE Registry, Int. J. Cancer 150 (1) (2022) 124–131; https://doi.org/10.1002/ijc.33785
F. Després, A. Forget, F.-Z. Kettani and L. Blais, Impact of patient reimbursement timing and patient out-of-pocket expenses on medication adherence in patients covered by private drug insurance plans, J. Manag. Care Spec. Pharm. 22 (5) (2016) 539–547; https://doi.org/10.18553/jmcp.2016.22.5.539
S. Schneeweiss, A. R. Patrick, M. Maclure, C. R. Dormuth and R. J. Glynn, Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment, Circulation 115 (16) (2007) 2128–2135; https://doi.org/10.1161/CIRCULATIONAHA.106.665992
M. E. Patterson, S. J. Blalock, A. J. Smith and M. D. Murray, Associations between prescription copayment levels and β-blocker medication adherence in commercially insured heart failure patients 50 years and older, Clin. Ther. 33 (5) (2011) 608–616; https://doi.org/10.1016/j.clinthera.2011.04.022
S. Gupta, M. A. McColl, S. J. Guilcher and K. Smith, Cost-related nonadherence to prescription medications in Canada: a scoping review, Patient Prefer. Adherence 12 (2018) 1699–1715; https://doi.org/10.2147/PPA.S170417
L. Husinka, P. H. Koerner, R. T. Miller and W. Trombatt, Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer, J. Drug Assess. 10 (1) (2021) 27–34; https://doi.org/10.1080/21556660.2020.1857103
A. Marra and G. Curigliano, Are all cyclin-dependent kinases 4/6 inhibitors created equal?, NPJ Breast Cancer 5 (2019) Article ID 27 (9 pages); https://doi.org/10.1038/s41523-019-0121-y
J. L. Grenard, B. A. Munjas, J. L. Adams, M. Suttorp, M. Maglione, E. A. McGlynn and W. F. Gellad, Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis, J. Gen. Intern. Med. 26 (10) (2011) 1175–1182; https://doi.org/10.1007/s11606-011-1704-y
B. T. Mausbach, R. B. Schwab and S. A. Irwin, Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis, Breast Cancer Res. Treat . 152 (2) (2015) 239–246; https://doi.org/10.1007/s10549-015-3471-7
C. Burgess, V. Cornelius, S. Love, J. Graham, M. Richards and A. Ramirez, Depression and anxiety in women with early breast cancer: five year observational cohort study, Br. Med. J. 330 (7493) (2005) 702–705; https://doi.org/10.1136/bmj.38343.670868.D3
K. M. Christie, B. E. Meyerowitz and R. C. Maly, Depression and sexual adjustment following breast cancer in low-income Hispanic and non-Hispanic white women, Psychooncology 19 (10) (2010) 1069–1077; https://doi.org/10.1002/pon.1661
F. Trinca, P. Infante, R. Dinis, M. Inácio, E. Bravo, J. Caravana, T. Reis and S. Marques, Depression and quality of life in patients with breast cancer undergoing chemotherapy and monoclonal antibodies, Ecancermedicalscience 13 (2019) Article ID 937 (20 pages); https://doi.org/10.3332/ecancer.2019.937
M. Thakur, R. Sharma, A. K. Mishra and K. R. Singh, Prevalence and psychobiological correlates of depression among breast cancer patients, Indian J. Surg. Oncol . 12 (2) (2021) 251–257; https://doi.org/10.1007/s13193-021-01296-7
C. Brito, C. Portela, M. Teixeira and L. De Vasconcellos, Adherence to hormone therapy among women with breast cancer, BMC Cancer 14 (2014) Article ID 397 (8 pages); https://doi.org/10.1186/1471-2407-14-397